PTHS

Pelthos Therapeutics Inc. (PTHS) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

R&D intensity of 3.0% of revenue suggests a relatively modest innovation footprint versus peers, limiting evidence of superior resource-efficiency leadership.

No disclosed stock-based compensation burden may reduce governance-linked ESG complexity, but it does not materially differentiate environmental stewardship versus peers.

Negative net debt to EBITDA indicates a net cash position, which can support lower financing pressure for sustainability investments, though peer ESG relevance is indirect.

Gross margin of 54.7% implies some operational efficiency, yet the data do not show a clear peer-leading environmental cost or emissions advantage.

Social

Score:

Zero stock-based compensation can reduce perceived pay-related dilution concerns, but it offers limited evidence of stronger workforce alignment than peers.

The available metrics provide no direct disclosure on labor practices, safety, diversity, or customer responsibility, leaving social positioning broadly unproven versus peers.

A net cash balance may support continuity in employee and stakeholder commitments, but this is an indirect benefit rather than a demonstrated social advantage.

R&D spending at 3.0% of revenue suggests some investment in product or service development, yet the data do not show a clear peer-relative social impact.

Governance

Score:

Zero stock-based compensation is a positive governance signal versus peers that rely heavily on equity pay, because it reduces dilution and incentive complexity.

Net cash and negative leverage metrics indicate balance-sheet conservatism, which can lower creditor pressure and support more stable governance execution than leveraged peers.

The absence of disclosed compensation expense in the provided metrics limits assessment of board oversight quality, so governance strength remains only moderately evidenced.

Gross profitability is solid, but without filing-based board, ownership, or control disclosures, the company cannot be judged as structurally stronger than peers.

Overall Score

Score:

PTHS appears broadly in line with peers on ESG based on limited disclosed metrics, with a modest governance edge from zero stock-based compensation and net cash.

Score Driver: Limited Disclosure Prevents Evidence Of A Clear Peer-Leading ESG Advantage.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Pelthos Therapeutics Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →